Oculis Holding AG Warrants (OCSAW NASDAQ) stock market data APIs
$6.0612
0.16(2.6%)
as of September 16, 2025
Try our APIs with
free plan!
Oculis Holding AG Warrants Financial Data Overview
Price chart is built with
Anychart
Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. Its product candidates in development includes OCS-01, a topical retinal candidate for diabetic macular edema; OCS-02, a topical biologic candidate for dry eye disease; and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
Prev. Close
6.0612
Open
6.2167
High
6.3753
Low
5.8818
52 wk Range
1.99-11.5
Market Cap
0
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Oculis Holding AG Warrants data using free add-ons & libraries
Get Oculis Holding AG Warrants Fundamental Data
Oculis Holding AG Warrants Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Oculis Holding AG Warrants News
New
Oculis Reports Q2 2025 Financial Results and Provides Company Update
Oculis Holding AG Focused execution in Q2 2025 to advance Oculis’ pipeline in ophthalmology and neuro-ophthalmology OCS-01: Both pivotal Ph3 DIAMOND trials are fully enrolled, with topline results...
Oculis Upsized Loan Facility to Access up to CHF 100 million
Oculis Holding AG ZUG, Switzerland, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on inn...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
